Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

por Friend, Reed, Bhutani, Manisha, Voorhees, Peter M, Usmani, Saad Z
Publicado 2017

Oprozomib in patients with newly diagnosed multiple myeloma

por Hari, Parameswaran, Matous, Jeffrey V., Voorhees, Peter M., Shain, Kenneth H., Obreja, Mihaela, Frye, John, Fujii, Hisaki, Jakubowiak, Andrzej J., Rossi, Davide, Sonneveld, Pieter
Publicado 2019

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma

por Foureau, David, Bhutani, Manisha, Guo, Fei, Rigby, Katherine, Leonidas, Marina, Tjaden, Elise, Fox, Andee, Atrash, Shebli, Paul, Barry, Voorhees, Peter M., Usmani, Saad Z.
Publicado 2021

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

por van Rhee, Frits, Casper, Corey, Voorhees, Peter M., Fayad, Luis E., van de Velde, Helgi, Vermeulen, Jessica, Qin, Xiang, Qi, Ming, Tromp, Brenda, Kurzrock, Razelle
Publicado 2015

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1

por Bringhen, Sara, Voorhees, Peter M., Plesner, Torben, Mellqvist, Ulf‐Henrik, Reeves, Brandi, Sonneveld, Pieter, Byrne, Catriona, Nordström, Eva, Harmenberg, Johan, Obermüller, Jakob, Richardson, Paul G.
Publicado 2021

Retrospective Review of Outcomes of Multiple Myeloma (MM) Patients With COVID-19 Infection (Two-Center Study)

por Ehsan, Hamid, Britt, Alec, Voorhees, Peter M, Paul, Barry, Bhutani, Manisha, Varga, Cindy, Chiad, Zane, Ragon, Brittany K., Abdallah, Al-Ola A., Ahmed, Nausheen, Atrash, Shebli
Publicado 2023

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

por Fonseca, Rafael, Usmani, Saad Z., Mehra, Maneesha, Slavcev, Mary, He, Jianming, Cote, Sarah, Lam, Annette, Ukropec, Jon, Maiese, Eric M., Nair, Sandhya, Potluri, Ravi, Voorhees, Peter M.
Publicado 2020

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma

por Atrash, Shebli, Robinson, Myra, Slaughter, Daniel, Aneralla, Amanda, Brown, Taylor, Robinson, Jordan, Ndiaye, Ami, Sprouse, Chelsea, Zhang, Qing, Symanowski, James T., Friend, Reed, Voorhees, Peter M., Usmani, Saad Z., Bhutani, Manisha
Publicado 2018

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma

por Foureau, David M., Paul, Barry A., Guo, Fei, Lipford, Edward H., Fesenkova, Kateryna, Tjaden, Elise, Drummond, Kendra, Bhutani, Manisha, Atrash, Shebli, Ndiaye, Ami, Varga, Cindy, Voorhees, Peter M., Usmani, Saad Z.
Publicado 2023

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

por Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Hoos, Axel, Gupta, Ira, Bragulat, Veronique, He, Zangdong, Opalinska, Joanna B., Cohen, Adam D.
Publicado 2019

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

por Popat, Rakesh, Lonial, Sagar, Voorhees, Peter M., Esposti, Simona Degli, Gorsh, Boris, Gupta, Ira, Opalinska, Joanna, Sapra, Sandhya, Piontek, Trisha, He, Zangdong, Kleinman, David, Schaumberg, Debra, Regnault, Antoine, Meunier, Juliette, Eliason, Laurie
Publicado 2023

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

por Foureau, David M., Bhutani, Manisha, Robinson, Myra, Guo, Fei, Pham, Duy, Buelow, Ben, Steuerwald, Nury, Rigby, Katherine, Tjaden, Elise, Leonidas, Marina, Paul, Barry A., Atrash, Shebli, Ndiaye, Ami, Symanowski, James T., Voorhees, Peter M., Usmani, Saad Z.
Publicado 2020

COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients

por Shahid, Zainab, Patrick, Alicia L., Wallander, Michelle L., Donahue, Erin E., Trufan, Sally J., Tan, Antoinette R., Hwang, Jimmy J., Burgess, Earle F., Ragon, Brittany, Ghosh, Nilanjan, Grunwald, Michael R., Voorhees, Peter M., Copelan, Edward A., Raghavan, Derek
Publicado 2023

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

por Richardson, Paul G., Lee, Hans C., Abdallah, Al-Ola, Cohen, Adam D., Kapoor, Prashant, Voorhees, Peter M., Hoos, Axel, Wang, Karrie, Baron, January, Piontek, Trisha, Byrne, Julie, Richmond, Scott, Jewell, Roxanne C., Opalinska, Joanna, Gupta, Ira, Lonial, Sagar
Publicado 2020

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

por D'Souza, Anita, Shah, Nina, Rodriguez, Cesar, Voorhees, Peter M., Weisel, Katja, Bueno, Orlando F., Pothacamury, Rajvineeth K., Freise, Kevin J., Yue, Susan, Ross, Jeremy A., Polepally, Akshanth R., Talati, Chetasi, Lee, Shane, Jin, Ziyi, Buelow, Ben, Vij, Ravi, Kumar, Shaji
Publicado 2022

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

por Yan, Xiaoyu, Clemens, Pamela L., Puchalski, Thomas, Lonial, Sagar, Lokhorst, Henk, Voorhees, Peter M., Usmani, Saad, Richardson, Paul G., Plesner, Torben, Liu, Kevin, Orlowski, Robert Z., Losic, Nedjad, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Ruixo, Juan Jose Perez, Zhou, Honghui, Xu, Xu Steven
Publicado 2017

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

por Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, Cohen, Adam D.
Publicado 2021

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

por Sborov, Douglas W., Baljevic, Muhamed, Reeves, Brandi, Laubach, Jacob, Efebera, Yvonne A., Rodriguez, Cesar, Costa, Luciano J., Chari, Ajai, Silbermann, Rebecca, Holstein, Sarah A., Anderson, Larry D., Kaufman, Jonathan L., Shah, Nina, Pei, Huiling, Patel, Sharmila, Cortoos, Annelore, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Voorhees, Peter M., Richardson, Paul G.
Publicado 2022

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

por Ferreri, Christopher J., Hildebrandt, Michelle A. T., Hashmi, Hamza, Shune, Leyla O., McGuirk, Joseph P., Sborov, Douglas W., Wagner, Charlotte B., Kocoglu, M. Hakan, Rapoport, Aaron, Atrash, Shebli, Voorhees, Peter M., Khouri, Jack, Dima, Danai, Afrough, Aimaz, Kaur, Gurbakhash, Anderson, Larry D., Simmons, Gary, Davis, James A., Kalariya, Nilesh, Peres, Lauren C., Lin, Yi, Janakiram, Murali, Nadeem, Omar, Alsina, Melissa, Locke, Frederick L., Sidana, Surbhi, Hansen, Doris K., Patel, Krina K., Castaneda Puglianini, Omar Alexis
Publicado 2023

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

por Leung, Nelson, Bridoux, Frank, Batuman, Vecihi, Chaidos, Aristeidis, Cockwell, Paul, D’Agati, Vivette D., Dispenzieri, Angela, Fervenza, Fernando C., Fermand, Jean-Paul, Gibbs, Simon, Gillmore, Julian D., Herrera, Guillermo A., Jaccard, Arnaud, Jevremovic, Dragan, Kastritis, Efstathios, Kukreti, Vishal, Kyle, Robert A., Lachmann, Helen J., Larsen, Christopher P., Ludwig, Heinz, Markowitz, Glen S., Merlini, Giampaolo, Mollee, Peter, Picken, Maria M., Rajkumar, Vincent S., Royal, Virginie, Sanders, Paul W., Sethi, Sanjeev, Venner, Christopher P., Voorhees, Peter M., Wechalekar, Ashutosh D., Weiss, Brendan M., Nasr, Samih H.
Publicado 2018